Literature DB >> 31602389

Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?

Thomas Seufferlein1, Carolina Simões2, Fernando Kude3, Thomas J Ettrich1.   

Abstract

Molecular diagnostics of metastatic colorectal cancer (mCRC) are coming of age. Whereas for many years RAS mutations were the only relevant molecular alterations examined in mCRC, nowadays the BRAF, HER2, and microsatellite instability status of a given tumor is gaining importance, since it has not only prognostic relevance but opens new avenues for therapeutic approaches. This review summarizes the recent advances in molecular approaches to mCRC and their therapeutic consequences and discusses novel approaches for molecular diagnostics in mCRC.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Colorectal cancer; Molecular approach; Personalized medicine

Year:  2019        PMID： 31602389      PMCID： PMC6738174          DOI： 10.1159/000500617

Source DB:  PubMed          Journal:  Visc Med        ISSN： 2297-4725


  22 in total

1.  Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

Authors:  Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2014-06-23       Impact factor: 4.481

2.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

Review 3.  New therapies and insights into the changing landscape of colorectal cancer.

Authors:  Scott Kopetz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-02       Impact factor: 46.802

4.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

5.  Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Authors:  C M Parseghian; J M Loree; V K Morris; X Liu; K K Clifton; S Napolitano; J T Henry; A A Pereira; E Vilar; B Johnson; B Kee; K Raghav; A Dasari; J Wu; N Garg; V M Raymond; K C Banks; A A Talasaz; R B Lanman; J H Strickler; D S Hong; R B Corcoran; M J Overman; S Kopetz
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

6.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

7.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

8.  BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.

Authors:  Zacharenia Saridaki; Maria Tzardi; Maria Sfakianaki; Chara Papadaki; Alexandra Voutsina; Aristea Kalykaki; Ippokratis Messaritakis; Kyriakos Mpananis; Dimitris Mavroudis; Efstathios Stathopoulos; Vassilis Georgoulias; John Souglakos
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

9.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

10.  Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Authors:  Sean P Pitroda; Nikolai N Khodarev; Lei Huang; Abhineet Uppal; Sean C Wightman; Sabha Ganai; Nora Joseph; Jason Pitt; Miguel Brown; Martin Forde; Kathy Mangold; Lai Xue; Christopher Weber; Jeremy P Segal; Sabah Kadri; Melinda E Stack; Sajid Khan; Philip Paty; Karen Kaul; Jorge Andrade; Kevin P White; Mark Talamonti; Mitchell C Posner; Samuel Hellman; Ralph R Weichselbaum
Journal:  Nat Commun       Date:  2018-05-04       Impact factor: 14.919
View more
  1 in total

Review 1.  Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.

Authors:  Guillermo Valenzuela; Joaquín Canepa; Carolina Simonetti; Loreto Solo de Zaldívar; Katherine Marcelain; Jaime González-Montero
Journal:  World J Clin Oncol       Date:  2021-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.